Lenox Wealth Advisors’s Alaunos Therapeutics TCRT Stock Holding History

Lenox Wealth Advisors’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$3K	Hold	33	–	–	﹤0.01%	622
2021 Q4	$5K	Hold	33	–	–	﹤0.01%	610
2021 Q3	$9K	Hold	33	–	–	﹤0.01%	489
2021 Q2	$13K	Hold	33	–	–	﹤0.01%	431
2021 Q1	$18K	Hold	33	–	–	﹤0.01%	331
2020 Q4	$13K	Hold	33	–	–	﹤0.01%	391
2020 Q3	$13K	Hold	33	–	–	﹤0.01%	349
2020 Q2	$16K	Hold	33	–	–	﹤0.01%	327
2020 Q1	$12K	Hold	33	–	–	﹤0.01%	325
2019 Q4	$24K	Hold	33	–	–	﹤0.01%	306
2019 Q3	$21K	Hold	33	–	–	﹤0.01%	296
2019 Q2	$29K	Hold	33	–	–	0.01%	186
2019 Q1	$19K	Hold	33	–	–	﹤0.01%	207
2018 Q4	$9K	Buy	+33	New	+$13K	﹤0.01%	263
2018 Q2	–	Sell	-1	Closed	–	–	641
2018 Q1	$0	Buy	+1	New	+$623	﹤0.01%	563

Other funds holding TCRT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

DCM

Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Lenox Wealth Advisors's TCRT Position: Q1 2022 in Review

Lenox Wealth Advisors held its Alaunos Therapeutics (TCRT) position steady in Q1 2022 at 33 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #622.

Lenox Wealth Advisors first reported a position in TCRT in Q1 2018 and has held it in 15 quarters since. The position peaked at $29K in Q2 2019. 148 funds tracked by Wall St. Rank hold TCRT as of Q1 2022.

Lenox Wealth Advisors held 33 shares of Alaunos Therapeutics worth $3K as of Q1 2022.
Lenox Wealth Advisors left its Alaunos Therapeutics share count unchanged in Q1 2022.
Alaunos Therapeutics made up ﹤0.01% of Lenox Wealth Advisors's portfolio in Q1 2022, its #622 holding.
Lenox Wealth Advisors first reported a position in Alaunos Therapeutics in Q1 2018 and has held it in 15 quarters since.
Lenox Wealth Advisors's Alaunos Therapeutics position peaked at $29K in Q2 2019.
148 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2022.

Based on Lenox Wealth Advisors's 13F filing for Q1 2022, filed 14 Apr 2022.